Cempra Company Profile (NASDAQ:CEMP)

About Cempra

Cempra logoCempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: CEMP
  • CUSIP: 15130J10
Key Metrics:
  • Previous Close: $4.05
  • 50 Day Moving Average: $3.22
  • 200 Day Moving Average: $12.79
  • 52-Week Range: $52,381,000.00 - $2.55
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.98
  • P/E Growth: 0.00
  • Market Cap: $212.14M
  • Outstanding Shares: 52,381,000
  • Beta: 0.95
Profitability:
  • Net Margins: -678.72%
  • Return on Equity: -59.94%
  • Return on Assets: -47.76%
Debt:
  • Debt-to-Equity Ratio: 0.05%
  • Current Ratio: 10.19%
  • Quick Ratio: 10.19%
Additional Links:
Companies Related to Cempra:

Analyst Ratings

Consensus Ratings for Cempra (NASDAQ:CEMP) (?)
Ratings Breakdown: 1 Sell Rating, 13 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.12)
Consensus Price Target: $13.74 (239.34% upside)

Analysts' Ratings History for Cempra (NASDAQ:CEMP)
Show:
DateFirmActionRatingPrice TargetDetails
2/24/2017Robert W. BairdReiterated RatingPositiveView Rating Details
1/12/2017J P Morgan Chase & CoReiterated RatingHoldView Rating Details
1/2/2017Cowen and CompanyReiterated RatingHoldView Rating Details
1/2/2017Cantor FitzgeraldSet Price TargetBuy$28.00View Rating Details
12/30/2016Needham & Company LLCReiterated RatingHoldView Rating Details
12/30/2016Roth CapitalDowngradeBuy -> Neutral$2.50View Rating Details
12/30/2016Morgan StanleyUpgradeUnderweight -> Equal Weight$5.00 -> $5.00View Rating Details
12/29/2016WBB SecuritiesDowngradeBuy -> Hold$40.00 -> $4.00View Rating Details
12/29/2016S&P Equity ResearchBoost Price Target$2.65 -> $3.15View Rating Details
12/29/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralView Rating Details
12/20/2016SunTrust Banks, Inc.DowngradeBuy -> Sell$18.00 -> $5.00View Rating Details
12/12/2016Jefferies Group LLCSet Price TargetHold$10.00View Rating Details
11/23/2016GabelliDowngradeBuy -> HoldView Rating Details
11/8/2016RBC Capital MarketsReiterated RatingBuy$27.50View Rating Details
11/3/2016Stifel NicolausDowngradeBuy -> Hold$37.00 -> $8.00View Rating Details
11/2/2016Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformView Rating Details
5/10/2016Janney Montgomery ScottReiterated RatingHoldView Rating Details
5/2/2016Leerink SwannReiterated RatingHoldView Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Cempra (NASDAQ:CEMP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017($0.59)N/AView Earnings Details
10/27/2016Q3($0.64)($0.62)$3.90 million$4.00 millionViewListenView Earnings Details
8/1/2016Q2($0.67)($0.51)$3.89 million$3.42 millionViewN/AView Earnings Details
5/2/2016Q1($0.63)($0.61)$3.94 million$2.70 millionViewN/AView Earnings Details
2/24/2016Q4($0.59)($0.48)$3.89 million$5.79 millionViewListenView Earnings Details
10/22/2015Q315($0.52)($0.63)$4.70 million$2.50 millionViewListenView Earnings Details
7/29/2015Q2($0.42)($0.57)$4.21 millionViewListenView Earnings Details
4/30/2015Q1($0.43)($0.41)$2.90 million$13.96 millionViewListenView Earnings Details
2/25/2015Q414($0.49)($0.46)$3.19 millionViewListenView Earnings Details
10/29/2014Q314($0.56)($0.34)$7.80 millionViewN/AView Earnings Details
7/29/2014Q214($0.56)($0.49)$2.56 million$1.90 millionViewN/AView Earnings Details
4/29/2014Q114($0.48)($0.51)$2.10 million$3.10 millionViewN/AView Earnings Details
2/27/2014Q413($0.42)($0.51)$1.25 million$2.07 millionViewN/AView Earnings Details
10/29/2013Q313($0.29)($0.41)$0.46 million$1.20 millionViewN/AView Earnings Details
7/30/2013Q3 2013($0.42)($0.16)$5.13 million$4.60 millionViewN/AView Earnings Details
11/8/2012Q312($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cempra (NASDAQ:CEMP)
Current Year EPS Consensus Estimate: $-2.34 EPS
Next Year EPS Consensus Estimate: $-2.05 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($0.61)($0.48)($0.56)
Q2 20166($0.68)($0.44)($0.58)
Q3 20165($0.78)($0.46)($0.62)
Q4 20165($0.94)($0.50)($0.73)
Q1 20172($1.01)($0.54)($0.78)
Q2 20172($0.94)($0.53)($0.74)
Q3 20172($0.71)($0.56)($0.64)
Q4 20172($0.60)($0.52)($0.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cempra (NASDAQ:CEMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cempra (NASDAQ:CEMP)
Insider Ownership Percentage: 17.80%
Institutional Ownership Percentage: 79.92%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/13/2017Dov A Md GoldsteinDirectorSell105,460$3.40$358,564.00View SEC Filing  
1/6/2017Dov A Md GoldsteinDirectorSell937,600$3.41$3,197,216.00View SEC Filing  
1/3/2017David N GillDirectorBuy5,000$2.94$14,700.00View SEC Filing  
3/1/2016David MooreInsiderBuy500$16.18$8,090.00View SEC Filing  
1/4/2016Dov A. Md GoldsteinDirectorSell842$30.06$25,310.52View SEC Filing  
12/15/2015David W. OldachinsiderSell10,000$30.27$302,700.00View SEC Filing  
11/9/2015David W. OldachinsiderSell12,200$28.78$351,116.00View SEC Filing  
10/26/2015Garheng KongDirectorBuy2,830$17.43$49,326.90View SEC Filing  
6/22/2015Dov A Md GoldsteinDirectorSell50,000$35.74$1,787,000.00View SEC Filing  
5/23/2014John JohnsonDirectorBuy10,000$9.10$91,000.00View SEC Filing  
6/19/2013P Sherrill NeffDirectorBuy265,000$7.00$1,855,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cempra (NASDAQ:CEMP)
DateHeadline
reuters.com logoCempra's bacterial skin infection drug clears study, shares surge (NASDAQ:CEMP)
in.reuters.com - February 25 at 9:04 PM
reuters.com logoREFILE-Cempra's bacterial skin infection drug succeeds in key study (NASDAQ:CEMP)
www.reuters.com - February 25 at 9:04 PM
News IconShares of Cempra Inc. (NASDAQ: CEMP) Soar 28.57% On Positive Phase 3 Study Results (NASDAQ:CEMP)
streetregister.com - February 25 at 4:04 PM
marketexclusive.com logoAnalyst Activity – Robert W. Baird Reiterates Positive on Cempra (NASDAQ:CEMP) (NASDAQ:CEMP)
marketexclusive.com - February 25 at 2:25 AM
biz.yahoo.com logoCEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:CEMP)
us.rd.yahoo.com - February 25 at 2:25 AM
News IconCempra stock soars after positive trial results (NASDAQ:CEMP)
www.heraldsun.com - February 24 at 9:24 PM
4-traders.com logoNetworkNewsBreaks – Cempra, Inc. (NASDAQ: CEMP) – Phase 3 Study of Fusidic Acid Achieves Primary Endpoint; Shares Rise (NASDAQ:CEMP)
www.4-traders.com - February 24 at 9:24 PM
News IconCempra success: Taksta takes ABSSSI to task in phase III (NASDAQ:CEMP)
www.bioworld.com - February 24 at 9:24 PM
News IconCempra's bacterial skin infection drug succeeds in key study (NASDAQ:CEMP)
www.channelnewsasia.com - February 24 at 9:24 PM
smarteranalyst.com logoCempra Inc (CEMP) Shares Jump as Fusidic Acid Gets Closer to FDA Approval (NASDAQ:CEMP)
www.smarteranalyst.com - February 24 at 9:24 PM
us.rd.yahoo.com logoCempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI (NASDAQ:CEMP)
us.rd.yahoo.com - February 24 at 9:24 PM
us.rd.yahoo.com logo7:01 am Cempra announces positive topline results from a phase 3 study of oral fusidic acid in 716 patients with acute bacterial skin and skin structure infections (:ABSSSI); fusidic acid met primary endpoint and secondary efficacy endpoint (NASDAQ:CEMP)
us.rd.yahoo.com - February 24 at 9:24 PM
News IconBustling Stock in Focus: Cempra, Inc. (NASDAQ:CEMP) - Winfield Review (NASDAQ:CEMP)
winfieldreview.com - February 24 at 4:23 PM
News IconA Keen Look At The Chart For Cempra, Inc. (CEMP) - NY Stock News (NASDAQ:CEMP)
nystocknews.com - February 24 at 4:23 PM
bizjournals.com logoCempra shares up following skin infection trial results, but still a long way from full recovery (NASDAQ:CEMP)
www.bizjournals.com - February 24 at 4:23 PM
News IconEarnings And Analyst Opinion Offer Spending Insights: IntelliPharmaCeutics International Inc. (IPCI), Cempra, Inc ... - Post Analyst (NASDAQ:CEMP)
postanalyst.com - February 24 at 12:37 PM
News IconNumbers in Focus for Cempra, Inc. (NASDAQ:CEMP) - BVN (NASDAQ:CEMP)
bvnewsjournal.com - February 24 at 12:37 PM
News IconTurbulence Hits These Shares as Volume Spikes: Cempra, Inc. (NASDAQ:CEMP) - Aiken Advocate (NASDAQ:CEMP)
aikenadvocate.com - February 24 at 12:36 PM
schaeffersresearch.com logoJC Penney, Cempra, Accelerate Diagnostics News Today - Schaeffers Research (blog) (NASDAQ:CEMP)
www.schaeffersresearch.com - February 24 at 12:36 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Cempra, Acacia ... - Nasdaq - Nasdaq (NASDAQ:CEMP)
www.nasdaq.com - February 24 at 12:36 PM
reuters.com logoCempra's bacterial skin infection drug clears study, shares surge - Reuters (NASDAQ:CEMP)
www.reuters.com - February 24 at 12:36 PM
finance.yahoo.com logoIs This the Turnaround Cempra Has Been Looking For? (NASDAQ:CEMP)
finance.yahoo.com - February 24 at 12:36 PM
News IconAnalysts Peer Into Their Crystal Balls For Cempra, Inc. (NASDAQ:CEMP): Where Is It headed? - Winfield Review (NASDAQ:CEMP)
winfieldreview.com - February 21 at 2:11 PM
News IconCempra, Inc. NASDAQ:CEMP Volatility at Extreme Levels - Aiken Advocate (NASDAQ:CEMP)
aikenadvocate.com - February 21 at 2:11 PM
News IconCareer briefs: Fletcher named Realtor of Year (NASDAQ:CEMP)
www.heraldsun.com - February 17 at 5:58 PM
streetinsider.com logoForm 4 CEMPRA, INC. For: Jan 03 Filed by: GOLDSTEIN DOV A MD (NASDAQ:CEMP)
www.streetinsider.com - February 16 at 9:19 PM
streetinsider.com logoForm 4 CEMPRA, INC. For: Jan 03 Filed by: GOLDSTEIN DOV A MD (NASDAQ:CEMP)
www.streetinsider.com - February 16 at 9:19 PM
News IconTrading View on Shares of Cempra Inc. (CEMP) - BVN (NASDAQ:CEMP)
bvnewsjournal.com - February 14 at 4:59 PM
finance.yahoo.com logoCempra to Report Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:CEMP)
finance.yahoo.com - February 14 at 4:59 PM
News IconForward Earnings Estimate of Cempra, Inc.(CEMP) - Highland Mirror (NASDAQ:CEMP)
www.highlandmirror.com - February 11 at 9:21 PM
4-traders.com logoSarepta Therapeutics : Biotech Stocks on Investors' Radar -- Amicus Therapeutics, Cempra, Ophthotech, and Sarepta Therapeutics (NASDAQ:CEMP)
www.4-traders.com - February 10 at 4:30 PM
News IconBiotech Stocks on Investors' Radar -- Amicus Therapeutics, Cempra, Ophthotech, and Sarepta Therapeutics (NASDAQ:CEMP)
www.medindia.net - February 10 at 4:30 PM
seekingalpha.com logoCempra's Solithromycin And The Great FDA Echo Chamber - Seeking Alpha (NASDAQ:CEMP)
seekingalpha.com - February 9 at 9:35 PM
finance.yahoo.com logoCempra to Present at Upcoming Investor Conferences (NASDAQ:CEMP)
finance.yahoo.com - February 8 at 4:31 PM
finance.yahoo.com logoCORRECTING and REPLACING -- Cempra to Present at Upcoming Investor Conferences (NASDAQ:CEMP)
finance.yahoo.com - February 8 at 4:31 PM
News IconMarinus (NASDAQ: MRNS) Names Michael R. Dougherty to Board, Prepares to Initiate Phase 2 Studies of Ganaxolone (NASDAQ:CEMP)
missionir.com - February 2 at 4:30 PM
4-traders.com logoCempra : to Present at J.P. Morgan Healthcare Conference (NASDAQ:CEMP)
www.4-traders.com - February 2 at 4:30 PM
News IconEarnings Forecast Research on Cempra, Inc. (CEMP) - Morning Outlook (NASDAQ:CEMP)
www.morningoutlook.com - February 1 at 9:32 PM
News IconNews Impact Score Of Cempra, Inc. (NASDAQ:CEMP) At 100 - Stock Observer (NASDAQ:CEMP)
www.thestockobserver.com - February 1 at 9:32 PM
News IconStock Vacillating as Volatility Hits a High Point For Cempra, Inc. (NASDAQ:CEMP) - Wall Street Beacon (NASDAQ:CEMP)
wsbeacon.com - February 1 at 2:42 AM
News IconVolatility Watch on Shares of Cempra, Inc. (NASDAQ:CEMP) - Gilbert Daily (NASDAQ:CEMP)
gilbertdaily.com - January 30 at 5:45 AM
istreetwire.com logoStocks Under Review: Intersil Corporation (ISIL), Cempra, Inc. (CEMP), PacWest Bancorp (PACW) - iStreetWire (NASDAQ:CEMP)
istreetwire.com - January 27 at 5:33 PM
News IconEarnings in Full Force, Analysts Take Aim at Cempra, Inc. (NASDAQ:CEMP) - Wall Street Beacon (NASDAQ:CEMP)
wsbeacon.com - January 26 at 10:06 PM
News IconPriming The Pump: Stock Volatility Spotted in Cempra, Inc. (NASDAQ:CEMP) - Wall Street Beacon (NASDAQ:CEMP)
wsbeacon.com - January 24 at 2:06 AM
finance.yahoo.com logoCempra (CEMP): An Off-the-Radar Potential Winner (NASDAQ:CEMP)
finance.yahoo.com - January 23 at 4:04 PM
investornewswire.com logoCempra, Inc. (NASDAQ:CEMP) Records An Impact Score Of 25 - Investor Newswire (NASDAQ:CEMP)
www.investornewswire.com - January 22 at 9:18 PM
News IconCempra Inc. (CEMP) Receives $9.72 Average PT from Brokerages (NASDAQ:CEMP)
larampadinapoli.com - January 22 at 4:15 PM
News IconEPS Of Cempra, Inc. (NASDAQ:CEMP) At $-0.57 - Stock Observer (NASDAQ:CEMP)
www.thestockobserver.com - January 21 at 4:17 PM
News IconCempra, Inc. (CEMP) Director Sells 105460 Shares of Stock (NASDAQ:CEMP)
diariocatolico.net - January 21 at 3:25 AM
News IconThe Key Figures To Watch From Cempra, Inc. (NASDAQ:CEMP) Earnings (NASDAQ:CEMP)
xboxonezone.com - January 21 at 3:25 AM

Social

What is Cempra's stock symbol?

Cempra trades on the NASDAQ under the ticker symbol "CEMP."

Where is Cempra's stock going? Where will Cempra's stock price be in 2017?

17 equities research analysts have issued twelve-month price targets for Cempra's stock. Their predictions range from $2.50 to $32.00. On average, they anticipate Cempra's share price to reach $13.74 in the next twelve months.

When will Cempra announce their earnings?

Cempra is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

What are analysts saying about Cempra stock?

Here are some recent quotes from research analysts about Cempra stock:

  • Robert W. Baird analysts commented, "Cempra reported positive Phase 3 data for Taksta (fusidic acid) in acute bacterial skin and skin structure infections (ABSSSI). Taksta showed non-inferiority to linezolid, and was well-tolerated in the study. Given the turbulence in the stock since solithromycin's AdCom and briefing documents, the stock has been up as much as 50% today on the news. However, we continue to believe that the market potential for Taksta is too limited to see value in." (2/24/2017)
  • According to Zacks Investment Research, "Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. " (1/17/2017)

  • Cowen and Company analysts commented, "ICPT recently launched Ocaliva for PBC in the US." (6/24/2016)

  • Needham & Company LLC analysts commented, "Cempra hosted an investor and analyst mtg yesterday in NYC. Several KOLs presented views on target indication Community Acquired Bacterial Pneumonia (CABP) and role of solithromycin (Solithera). High macrolide resistance and consequences of increased use of fluoroquinolones (safety profile and C. difficile) were cited as concerns. KOL panel lamented that physicians are forced to either over-treat (w/ fluoroquinolone) or under-treat (w/ macrolide) and viewed Solithera as a helpful solution. Cempra Phase 3 development program positioned Solithera as an antibiotic with the safety profile of a macrolide and efficacy of a fluoroquinolone. Amongst antibiotics in development, Solithera is uniquely suited for treatment of outpatient respiratory infections. Mgmt guided for pricing to maximize access (less than $400-500 list price) and will negotiate tier II formulary placement ($35 copay). Payers have few concerns w/ acute care products. As a reminder, essentially all other antibiotics in clinical development are geared toward hospital, not retail setting. We expect Cempra to have moderate success in commercializing the drug independently, due to challenges for a biotech company in penetrating urgent and primary care. Key hurdles include creating broad patient and physician awareness of macrolide resistance and fluoroquinolone FDA safety warnings. Although the commercial opportunity is probably larger in hands of Big Pharma, we believe the share price does not reflect what Cempra can accomplish independently." (6/24/2016)

Who owns Cempra stock?

Cempra's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (10.58%), State Street Corp (4.07%), Hodges Capital Management Inc. (1.91%), Renaissance Technologies LLC (1.17%), Palo Alto Investors LLC (0.65%) and Oxford Asset Management (0.52%). Company insiders that own Cempra stock include David Moore, David N Gill, David W Oldach, Dov A Md Goldstein and Garheng Kong.

Who sold Cempra stock? Who is selling Cempra stock?

Cempra's stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, FMR LLC, Gabelli Funds LLC and Gamco Investors INC. ET AL.

Who bought Cempra stock? Who is buying Cempra stock?

Cempra's stock was purchased by a variety of institutional investors in the last quarter, including Hodges Capital Management Inc., State Street Corp, Renaissance Technologies LLC, Oxford Asset Management, Tudor Investment Corp Et Al, Guggenheim Capital LLC, Commonwealth of Pennsylvania Public School Empls Retrmt SYS and Bogle Investment Management L P DE. Company insiders that have bought Cempra stock in the last two years include David Moore, David N Gill and Garheng Kong.

How do I buy Cempra stock?

Shares of Cempra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cempra stock cost?

One share of Cempra stock can currently be purchased for approximately $4.05.

Cempra (NASDAQ:CEMP) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Cempra (NASDAQ:CEMP)

Earnings History Chart

Earnings by Quarter for Cempra (NASDAQ:CEMP)

Dividend History Chart

Dividend Payments by Quarter for Cempra (NASDAQ:CEMP)

Last Updated on 2/26/2017 by MarketBeat.com Staff